Bonomini et al
Mechanism of
Action
EPO receptor
activation
EPO receptor
activation
Agonistic antibodies to
the EPO receptor
EPO receptor
activation
Inducers of dimerization
of EPO receptor
intracellular domain
Chemical inducer of
dimerization (CID)
EPO receptor
activation
Agents
Reference
11-14
15-21
22-24
25
assigned 1:1:1 to FG-4592 low or high dose or placebo. At the end of the 8-week treatment period,
participants showed mean maximum Hb level increases from baseline of 2.6 g/dL in the high-dose
cohort and 1.8 g/dL in the low-dose cohort,
compared to 0.7 g/dL in the placebo group. The
percentage of patients achieving Hb levels $ 11 g/dL
was higher in those receiving the active drug than
placebo. Interestingly, patients who received roxadustat showed small decreases in blood pressure similar
to the placebo group. In still another study, FG-4592
was found effective in achieving anemia correction in
ESA-naive patients receiving peritoneal dialysis, with
a safety prole similar to the HD population.42
Akebia Therapeutics is developing another prolyl
hydroxylase inhibitor, AKB-6548. After successfully
undergoing phase 2a clinical development in CKD
stages 3 and 4, the drug has recently been evaluated in
a phase 2b, randomized, double-blind, placebocontrolled study.43 This 20-week study enrolled 209
nondialysis-dependent patients with CKD stages 3 to
5 who were randomly assigned 2:1 to active treatment
or placebo. The initial dose was 450 mg once daily,
with dose adjusted in accordance to the patients Hb
level response based on the AKB-6548 titration algorithm. Preliminary results showed that the primary
end point, dened as achieving or maintaining mean
Hb levels $ 11 g/dL or increasing Hb $ 1.2 g/dL
above the pretreatment value, was met in 54.9% who
received AKB-6548 compared with 10.3% in the
placebo group. The drug was generally well tolerated.
A phase 2 open-label study designed to examine the
efcacy, safety, and tolerability of AKB-6548 in HD
patients is ongoing (ClinicalTrials.gov identier
NCT02260193).
GlaxoSmithKline are also developing an HIF
prolyl hydroxylase inhibitor (GSK1278863). In 2011,
they concluded a phase 2a, randomized, single-blind,
135
Bonomini et al
Company
FG-4592 (Roxadustat)
Fibrogena
AKB-6548
GSK1278863
Akebia Therapeutics
Glaxo Smith Kline
Bayer Pharmaceuticals
Akros Pharmaceuticals
Daiichi Sankyo
Phase 2 studies completed (NDD CKD, HD, PD); phase 3 studies ongoing
(NDD CKD, HD, PD)
Phase 2 studies completed (NDD CKD) or ongoing but not recruiting (HD)
Phase 2a studies completed (NDD-CKD, HD); phase 2b studies ongoing, but
not recruiting (NDD CKD)
Phase 2b studies ongoing (NDD CKD, HD)
Phase 1 study completed (HD)
Phase 1 study ongoing (CKD 3b-4)
Abbreviations: CKD, chronic kidney disease; HD, hemodialysis; NDD, nondialysis-dependent; PD, peritoneal dialysis.
a
Collaboration with Astra Zeneca in the United States and China and with Astellas Pharma for Europe, Japan, the Middle East, and
South Africa.
Bonomini et al
138
CONCLUSIONS
The development of new strategies to treat anemia is
still an evolving and fascinating area of experimental
and clinical research. At present, the most promising
class of agents seems to be HIF stabilizers, as evident
in the number of molecules currently under development. This class of drug stimulates erythropoiesis by
physiologic concentrations of endogenous EPO,
which may translate into a clinical advantage because
concerns for ESA safety are higher at the high doses.
However, these theoretical advantages will need to be
demonstrated clinically in large trials. Conversely, the
class needs to be proved safe in light of the potential
risks for increases in levels of VEGF and related factors and the possibility of widespread stimulation of
complex pathways leading to unexpected side effects.
The nal judgment of benet/risks of these agents will
be possible only after the completion of large longterm safety studies testing hard end points.
EMPs were a promising class. They had the advantages of long-acting ESAs with the potential of
being less expensive than short-acting ESAs. Unfortunately, the experience with peginesatide and the fact
that the cause of these adverse events has not yet been
discovered seems to be halting development of the
molecule and seriously endangering further development of other agents in that class. Sotatercept, which
traps circulating activin, is another interesting drug
given its potential for not only correcting anemia but
also checking osteoporosis. This may be of importance considering that the CKD population is
becoming older and frailer.
ACKNOWLEDGEMENTS
Support: None.
Financial Disclosure: Dr Del Vecchio has served on the advisory board of Astellas. Dr Locatelli has served on the advisory
boards of Akebia, Amgen, Astellas, Fibrogen, Genzyme, GSK,
Fresenius Medical Care, Janssen Cilag, Pharmacosmos, Keryx,
and ZS Pharma and has been a speaker at a meeting supported by
Amgen, Asahi Casei, Roche, and ZS Pharma. The remaining authors declare that they have no relevant nancial interests.
REFERENCES
1. Kausz AT, Levey AS. The care of patients with chronic
kidney disease. J Gen Intern Med. 2002;17(8):658-662.
2. Winearls CG, Oliver DO, Pippard MJ, Reid C,
Downing MR, Cotes PM. Effect of human erythropoietin derived
from recombinant DNA on the anaemia of patients maintained by
chronic haemodialysis. Lancet. 1986;2(8517):1175-1178.
3. Jelkmann W. The ESA scenario gets complex: from biosimilar epoetins to activin traps. Nephrol Dial Transplant.
2015;30(4):553-559.
4. Singh AK, Szczech L, Tang KL, et al. Correction of anemia
with epoetin alfa in chronic kidney disease. N Engl J Med.
2006;355(20):2085-2098.
5. Dreke TB, Locatelli F, Clyne N, et al. Normalization of
hemoglobin level in patients with chronic kidney disease and
anemia. N Engl J Med. 2006;355(20):2071-2084.
139
Bonomini et al
6. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl
J Med. 2009;361(21):2019-2032.
7. Pisoni RL, Fuller DS, Bieber BA, et al. The DOPPS Practice
Monitor for US dialysis care: trends through August 2011. Am J
Kidney Dis. 2012;60(1):160-165.
8. KDIGO Anemia Work Group. KDIGO clinical practice
guideline for anemia in chronic kidney disease. Kidney Int Suppl.
2012;2:S279-S335.
9. Locatelli F, Brny P, Covic A, et al; ERA-EDTA ERBP
Advisory Board. Kidney Disease: Improving Global Outcomes
guidelines on anaemia management in chronic kidney disease: a
European Renal Best Practice position statement. Nephrol Dial
Transplant. 2013;28(6):1346-1359.
10. Hung SC, Tarng DC. ESA and iron therapy in chronic
kidney disease: a balance between patient safety and hemoglobin
target. Kidney Int. 2014;86(4):676-678.
11. Sathyanarayana P, Houde E, Marshall D, et al. CNTO 530
functions as a potent EPO mimetic via unique sustained effects
on bone marrow proerythroblast pools. Blood. 2009;113(20):
4955-4962.
12. Bugelski PJ, Makropoulos D, Spinka-Doms T, et al. Differential effects of long-lived erythropoietin receptor agonists in
rats. Pharm Anal Acta. 2011;2(7):133.
13. Greindl A, Kessler C, Breuer B, et al. AGEM400(HES), a
novel erythropoietin mimetic peptide conjugated to hydroxyethyl
starch with excellent in vitro efcacy. Open Hematol J. 2010;4:1-14.
14. Kessler C, Greindl A, Breuer B, et al. Erythropoietin
mimetic compound AGEM400(HES) binds to the same receptor as
erythropoietin but displays a different spectrum of activities.
Cytokine. 2012;57(2):226-237.
15. Dalle B, Henri A, Rouyer-Fessard P, et al. Dimeric erythropoietin fusion protein with enhanced erythropoietic activity
in vitro and in vivo. Blood. 2001;97(12):3776-3782.
16. Sytkowski AJ, Lunn ED, Risinger MA, Davis KL. An
erythropoietin fusion protein comprised of identical repeating
domains exhibits enhanced biological properties. J Biol Chem.
1999;274(35):24773-24778.
17. Fares FA, Ganem S, Hajouj T, Agai E. Development of a longacting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of
human erythropoietin. Endocrinology. 2007;48(10):5081-5087.
18. Fares F, Havron A, Fima E. Designing a long acting
erythropoietin by fusing three carboxyl-terminal peptides of human chorionic gonadotropin b subunit to the n-terminal coding
sequence. Int J Cell Biol. 2011;2011:275063.
19. Schriebl K, Trummer E, Lattenmayer C, et al. Biochemical
characterization of rhEPO-Fc fusion protein expressed in CHO
cells. Protein Expr Purif. 2006;49(2):265-275.
20. Penno CA, Kawabe Y, Ito A, Kamihita M. Production of
recombinant human erythropoietin/Fc fusion protein by genetically manipulated chickens. Transgenic Res. 2010;19(2):187-195.
21. Joung CH, Shin JY, Koo JK, et al. Production and characterization of long-acting recombinant human albumin-EPO
fusion protein expressed in CHO cell. Protein Expr Purif.
2009;68(2):137-145.
22. Schneider H, Chaovapong W, Matthews DJ, et al. Homodimerization of erythropoietin receptor by a bivalent monoclonal
antibody triggers cell proliferation and differentiation of erythroid
precursors. Blood. 1997;89(2):473-482.
23. Elliott S, Lorenzini T, Yanagihara D, Chang D, Elliott G.
Activation of the erythropoietin (EPO) receptor by bivalent antiEPO receptor antibodies. J Biol Chem. 1996;271(40):24691-24697.
140
141
Bonomini et al
77. Lotinun S, Pearsall RS, Davies MV, et al. A soluble activin
receptor type IIA fusion protein (ACE-011) increases bone mass
via a dual anabolic-antiresorptive effect in Cynomolgus monkeys.
Bone. 2010;46(4):1082-1088.
78. Pearsall RS, Canalis E, Cornwall-Brady M, et al.
A soluble activin type IIA receptor induces bone formation and
improves skeletal integrity. Proc Natl Acad Sci U S A. 2008;105(19):
7082-7087.
79. Fang Y, Agapova OA, Sugatani T, Malluche H,
Hruska KA. Treatment of the CKD-MBD with a ligand trap for the
activin receptor type 2A [ASN abstract FR-PO816]. J Am Soc
Nephrol. 2014;25:557A.
80. Hruska KA, Agapova OA, Fang Y, Sugatani T,
Seifert ME, Sung V. Chronic kidney disease (CKD) stimulates
activin and endothelial to mesenchymal transition (EnMT),
which causes vascular calcication and is inhibited by an activin
ligand trap [ASN abstract SA-OR063]. J Am Soc Nephrol.
2014;25:95A.
81. Leonard MB. A structural approach to skeletal fragility in
chronic kidney disease. Semin Nephrol. 2009;29(2):133-143.
82. Malluche H, Hurska K, Singh HN, Smith WT. Sotatercept: initial signal-seeking quantitative computed tomography
results for bone mass and vascular calcication in hemodialysis
patients treated with escalating doses: interim analysis of ACE011-REN-001 [ASN abstract TH-PO602]. J Am Soc Nephrol.
2014;25:245A.
83. Suragani RN, Cadena SM, Cawley SM, et al. Transforming
growth factor-b superfamily ligand trap ACE-536 corrects anemia
by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):
408-414.
84. Attie KM, Allison MJ, McClure T, et al. A phase 1 study of
ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89(7):766-770.
85. Livnah O, Stura EA, Johnson DL. Functional mimicry of a
protein hormone by a peptide agonist: the EPO receptor complex
at 2.8 A. Science. 1996;273(5274):464-471.
86. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as
potent mimetics of the protein hormone erythropoietin. Science.
1996;273(5274):458-464.
87. Johnson DL, Farrell FX, Barbone FP, et al. Identication of
a 13 amino acid peptide mimetic of erythropoietin and description
of amino acids critical for the mimetic activity of EMP1.
Biochemistry. 1998;37(11):3699-3710.
88. Huang C. Receptor-Fc fusion therapeutics, traps, and
MIMETIBODY technology. Curr Opin Biotechnol. 2009;20(6):
692-699.
89. Bouman-Thio E, Franson K, Miller B, et al. A phase I,
single and fractionated, ascending-dose study evaluating the
safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein
(CNTO 528) in healthy male subjects. J Clin Pharmacol.
2008;48(10):1197-1207.
142